コーパス検索結果 (rifght1)
通し番号をクリックするとPubMedの該当ページを表示します
1 rgery that were rated as inappropriate decreased from 2,956 patients in 2010 to 911 patients in 2014, a reduction of 69%.
3 , in HIV disease progression by analyzing a large number of patients in 3 cohorts with different HIV disease progression
4 e a framework for future tailoring, triage, and therapy for patients in a more personalized and precise manner.
10 Bidirectional block was achieved in 56 of 57 patients in group A (98.2%) and 50 of 57 patients in group B
12 has been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-cancer drug
14 Ticagrelor appears to provide higher value for patients in several recognized high-risk subgroups.
16 erosclerotic stenosis interaction in a subgroup analysis of patients in the Acute Stroke or Transient Ischaemic Attack Tr
21 rse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients
23 Minor adverse events occurred in 22% of patients in the control group and none of the patients in the
26 Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, were a strong, independent
27 of DM and the glycosylated hemoglobin (HbA1c) levels of the patients in the DM group were recorded.
28 to be associated with a 38% excess fracture risk among T2DM patients in the early stages of the disease.
29 any grade) prompted treatment discontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients
32 odies was similar in the treatment groups (five [2%] of 268 patients in the GP2013-CVP; three [1%] in the R-CVP group).
35 icant difference observed between wildtype and heterozygous patients in the majority of the outcomes studied.
36 Serious adverse events were experienced by 35 (18%) patients in the olaparib group and eight (8%) patients in the
37 of grade 3 or worse severity were anaemia (38 [19%] of 195 patients in the olaparib group vs two [2%] of 99 patients in
38 disease (n=2 in the PENFS group; n=1 in the sham group), 57 patients in the PENFS group and 47 patients in the sham group
39 he patients in the tranexamic acid group and in 2.8% of the patients in the placebo group (P=0.001), and seizures occurre
40 9%] of 195 patients in the olaparib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4
42 3 (62%) of 102 patients underwent PCS versus 93 (94%) of 99 patients in the primary surgery group.
43 Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in
44 1 in the sham group), 57 patients in the PENFS group and 47 patients in the sham group were included in the primary analy
45 red in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3
46 ac tamponade leading to reoperation occurred in 1.4% of the patients in the tranexamic acid group and in 2.8% of the pati
47 in whole blood samples from 150 participants, representing patients in the upper and lower quartile of BP response to TD
48 In the randomly assigned patients, 21 patients in the VRd group and 31 in the Rd group were deemed
50 We then retrospectively compared the patients in this study with all other concurrent patients at
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。